RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan.
2009-01-01 Scartozzi, Mario; Bearzi, I; Mandolesi, A; Loupakis, F; Zaniboni, A; Berardi, R; Pierantoni, C; Masi, G; Falcone, A; Cascinu, S.
CORRELATIONS BETWEEN CLINICAL RESPONSE TO CISPLATIN OR OXALIPLATIN CHEMOTHERAPY AND EXPRESSION OF THE MIS- MATCH REPAIR (MMR) AND P53 IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS)
2004-01-01 Franciosi, V; Scartozzi, Mario; Santinelli, A; Rindi, G; Camisa, R; Benedetti, G; Barbieri, R; Ardizzoni, A; Cascinu, S.
COX-2 and NF-KB overexpression does not predict for celecoxib activity in combination with gemcitabine (GEM) and oxaliplatin (LH-OP) in advanced pancreatic cancer (PC).
2006-01-01 Berardi, R; Scartozzi, Mario; Carbonari, G; Silva, Rr; Mari, D; Massacesi, C; Pierantoni, C; Squadroni, M; Antognoli, S; Cascinu, S.
EGFR downstream signaling pathway in primary colorectal tumours and related metastatic sites: optimizing EGFR targeted treatment options.
2005-01-01 Scartozzi, Mario; Bearzi, I; Berardi, R; Mandolesi, A; Pierantoni, C; Cascinu S., EGFR downstream signaling pathway in primary colorectal tumours; Ann Oncol, related metastatic sites: optimizing EGFR targeted treatment o. p. t. i. o. n. s.; In, Stampa
ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER: TOLERABILITY AND ACTIVITY OF CHEMOTHERAPY
2003-01-01 Saladino, T; Berardi, R; Scartozzi, Mario; Cellerino, R; Cascinu, S.
Epidermal growth factor receptor (EGFR) downstream signaling pathway in primary colorectal tumors and related metastatic sites: Optimizing EGFR targeted treatment options
2006-01-01 Scartozzi, Mario; Bearzi, I; Berardi, R; Mandolesi, A; Pierantoni, C; Cascinu, S.
Epidermal growth factor receptor (EGFR) gene copy number (GCN) detected by chromogenic in situ hybridization (CISH) correlates with clinical activity of irinotecan-cetuximab in colorectal cancer.
2008-01-01 Scartozzi, Mario; Bearzi, I; Pierantoni, C; Mandolesi, A; Berardi, R; Loupakis, F; Galizia, E; Zaniboni, A; Falcone, A; Cascinu, S.
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE PROMOTER METHYLATION IN PRIMARY COLORECTAL TUMOURS AND CORRESPONDING METASTATIC SITES: A NEW PERSPECTIVE FOR AN ‘‘OLD’’ THERAPEUTIC TARGET
2008-01-01 Pagliacci, A; Scartozzi, Mario; Bearzi, I; Mandolesi, A; Galizia, E; Pierantoni, C; Loupakis, F; Berardi, R; Zaniboni, A; Quadri, A; Zorzi, F; Biscotti, T; Labianca, R; Masi, G; Falcone, A; Cascinu, S.
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) STATUS IN DIFFERENT STAGES OF RESECTED NON-SMALL CELL LUNG CANCER (NSCLC): IMPLICATIONS FOR TREATMENT WITH EGFR-TARGETED MONOCLONAL ANTIBODIES
2006-01-01 Squadroni, M; Berardi, R; Scartozzi, Mario; Santinelli, A; Verdecchia, L; Valeri, G; Gasparini, S; Marmorale, C; Fianchini, A; Cascinu, S.
Epidermal growth factor receptor (EGFR) status in primary colorectal tumours does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted antibodies.
2004-01-01 Scartozzi, Mario; Bearzi, I; Berardi, R; Mandolesi, A; Freddari, F; Graziano, F; Catalano, V; Baldelli, Am; Silva, Rr; Cascinu, S.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ... 47
- 4 Contributo in Atti di Convegno ... 47
Data di pubblicazione
- 2012 7
- 2011 3
- 2010 5
- 2009 9
- 2008 7
- 2006 5
- 2005 2
- 2004 7
- 2003 2
Rivista
- ANNALS OF ONCOLOGY 26
- JOURNAL OF CLINICAL ONCOLOGY 16
- EUROPEAN JOURNAL OF CANCER 3
- JOURNAL OF HEPATOLOGY 1
Lingua
- eng 2
Accesso al fulltext
- no fulltext 47